Last reviewed · How we verify
FFP
FFP (Fresh Frozen Plasma) replaces clotting factors and other plasma proteins to restore hemostatic function in patients with coagulation deficiencies.
FFP (Fresh Frozen Plasma) replaces clotting factors and other plasma proteins to restore hemostatic function in patients with coagulation deficiencies. Used for Correction of coagulation factor deficiencies in acute bleeding, Reversal of warfarin or other anticoagulants (when specific reversal agents unavailable), Massive transfusion protocols.
At a glance
| Generic name | FFP |
|---|---|
| Also known as | Fresh Frozen Plasma, Octaplas |
| Sponsor | Erasmus Medical Center |
| Drug class | Blood product / Plasma derivative |
| Modality | Biologic |
| Therapeutic area | Hematology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
FFP is a blood product containing all vitamin K-dependent clotting factors (II, V, VII, X), fibrinogen, and other plasma proteins. It is used to correct multiple factor deficiencies when specific factor concentrates are unavailable or in acute bleeding situations. The mechanism relies on passive replacement of missing or depleted coagulation factors to restore normal clotting cascade function.
Approved indications
- Correction of coagulation factor deficiencies in acute bleeding
- Reversal of warfarin or other anticoagulants (when specific reversal agents unavailable)
- Massive transfusion protocols
- Disseminated intravascular coagulation (DIC)
- Thrombotic thrombocytopenic purpura (TTP) plasma exchange
Common side effects
- Volume overload / Fluid overload
- Transfusion-related acute lung injury (TRALI)
- Allergic reaction
- Transfusion-transmitted infection (rare with modern screening)
- Hyperkalemia
Key clinical trials
- Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB) (PHASE3)
- Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery (PHASE2)
- Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing Invasive Procedures (NA)
- FFP In Traumatic BRAin INjury (FIT-BRAIN) Trial (PHASE2, PHASE3)
- International Care Bundle Evaluation in Cerebral Hemorrhage Research (PHASE4)
- Fragility Fractures of the Pelvis (FFP)
- Clinical Trial Assessing Non-Inferiority of Freeze Dried Plasma to Fresh Frozen Plasma in Reversing Warfarin (PHASE2)
- Randomized Trial of Fresh Frozen Plasma Versus Albumin in Acute Burn Resuscitation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FFP CI brief — competitive landscape report
- FFP updates RSS · CI watch RSS
- Erasmus Medical Center portfolio CI